Fig. 3: Effect of elacestrant versus fulvestrant on ER-mediated transcription and translation. | npj Breast Cancer

Fig. 3: Effect of elacestrant versus fulvestrant on ER-mediated transcription and translation.

From: Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

Fig. 3: Effect of elacestrant versus fulvestrant on ER-mediated transcription and translation.The alternative text for this image may have been generated using AI.

A Log2 expression of E-regulated genes together with ESR1 in MCF7 and both MCF7-LTED cell lines after treatment with 10 nM fulvestrant or 100 nM elacestrant. All treatments were performed in the presence of 1 nM E2. B Heatmap displaying changes in hallmark pathways following treatment with 10 nM fulvestrant (FULV) or 100 nM elacestrant (EL) in MCF7, MCF7-LTEDwt and MCF7-LTEDY537C. C Effect of 100 nM elacestrant and 10 nM fulvestrant upon protein abundance of cell cycle markers and E-regulated proteins in MCF7, MCF7-LTEDwt and MCF7-LTEDY537C. (Data from n = 5 biological experiments, per treatment per cell line).

Back to article page